Revisiting Rose: strategies for reducing coronary heart disease
Open accessAbstract
The way we assess risk of coronary heart disease has become more accurate in recent years. How does this affect the efficacy of primary and secondary prevention strategies?
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The population strategy was long considered more cost-effective than the high-risk approach, but since the introduction of highly effective lipid-lowering drugs, improved smoking cessation programmes, and lower costs of antihypertensive drugs, the effectiveness of the high-risk approach has increased.
“For a long time the population strategy has been considered to be more costeffective than the high-risk approach but since the introduction of highly effective lipid lowering drugs, improvement in smoking cessation programmes and lower costs of antihypertensive drugs, the effectiveness of the high risk approach has increased.20”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works
Sick individuals and sick populations
ROSE, G. (1985) · International Journal of Epidemiology · doi:10.1093/ije/14.1.32 · Cited by 2,701 · see citing works
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251 · see citing works
The strategy of preventive medicine
(1993) · Choice Reviews Online · doi:10.5860/choice.30-5633 · Cited by 1,878 · see citing works
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834 · see citing works
A strategy to reduce cardiovascular disease by more than 80%
Wald, N., & Law, M. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1419 · Cited by 1,568 · see citing works
Adherence with statin therapy in elderly patients with and without acute coronary syndromes
Jackevicius, C. A. (2002) · JAMA · doi:10.1001/jama.288.4.462 · Cited by 1,077 · see citing works
The Strategy of Preventive Medicine
Rose, G. (1993) · doi:10.1093/oso/9780192624864.001.0001 · Cited by 1,069 · see citing works
Kuulasmaa, K., Tunstall‐Pedoe, H., Dobson, A. J., Fortmann, S. P., Sans, S., Tolonen, H. K., Evans, A., & Ferrario, M. (2000) · The Lancet · doi:10.1016/s0140-6736(99)11180-2 · Cited by 950 · see citing works
The National Cholesterol Education Program
Cleeman, J. I. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30638-3 · Cited by 711 · see citing works
Tunstall‐Pedoe, H., Vanuzzo, D., HOBBS, M. S. T., Mähönen, M., Čepaitis, Ž., Kuulasmaa, K., & Keil, U. (2000) · The Lancet · doi:10.1016/s0140-6736(99)11181-4 · Cited by 513 · see citing works
European guidelines on cardiovascular disease prevention in clinical practice
Backer, G. D., Ambrosioni, E., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.10.001 · Cited by 493 · see citing works
Genest, J. J., Frohlich, J. J., Fodor, G. J., & McPherson, R. (2003) · PubMed Central · Cited by 345 · see citing works
Emberson, J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.11.012 · Cited by 236 · see citing works
DeBacker, G., Ambrosioni, E., & Borch‐Johnsen, K. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.12.022 · Cited by 158 · see citing works
Liao, Y., McGee, D., Cooper, R., & Sutkowski, M. B. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70407-2 · Cited by 126 · see citing works
Shea, S., & Basch, C. E. (1990) · American Journal of Health Promotion · doi:10.4278/0890-1171-4.4.279 · Cited by 114 · see citing works
A strategy to reduce cardiovascular disease by more than 80%
British Medical Journal Publishing Group (2003) · BMJ · doi:10.1136/bmj.327.7415.586-b · Cited by 109 · see citing works
MacLean, D. R., Petrasovits, A., Nargundkar, M., Connelly, P. W., MacLeod, E., Edwards, A., & Hessel, P. (1992) · Europe PMC (PubMed Central) · Cited by 98 · see citing works
Adherence with statin therapy in elderly patients with and without acute coronary syndromes
Jackevicius, C. A., Mamdani, M., & Tu, J. V. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00915-7 · Cited by 74 · see citing works
Patient adherence: the next frontier in quality improvement
Heidenreich, P. A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.03.007 · Cited by 74 · see citing works
Long term persistence with statin treatment in daily medical practice: Table 1
Mantel-Teeuwisse, A. K., Goettsch, W., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2004) · Heart · doi:10.1136/hrt.2003.026187 · Cited by 74 · see citing works
Sick Individuals and Sick Populations
Rose, G. (2006) · Public Health Ethics · doi:10.1093/oso/9780195180848.003.0003 · Cited by 66 · see citing works
Sick individuals and sick populations
Rose, G. (2001) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.1590/s0042-96862001001000015 · Cited by 64 · see citing works
Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001.
Jackevicius, C. A., Tu, K., Filate, W. A., Brien, S., & Tu, J. V. (2003) · PubMed · Cited by 46 · see citing works
Assessing Population-Based Programs to Reduce Blood Cholesterol Level and Saturated Fats
Vartiainen, E., Heath, G. W., & Ford, E. S. (1991) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300005699 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490 · see citing works
Social epidemiology: social determinants of health in the United States: are we losing ground?
Berkman, L. F. (2009) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.031308.100310 · Cited by 230 · see citing works
Wells, S., Furness, S., Rafter, N., Horn, E., Whittaker, R., Stewart, A., Moodabe, K., Roseman, P., Selak, V., Bramley, D., et al. (2008) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3282f13af4 · Cited by 109 · see citing works
Review on cardiovascular risk prediction
Ruwanpathirana, T., Owen, A., & Reid, C. M. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12110 · Cited by 31 · see citing works
- Authors
- Manuel, D. G., Lim, J., Tanuseputro, P., Anderson, G. M., Alter, D. A., Laupacis, A., & Mustard, C. A.
- Affiliations
- Institute for Clinical Evaluative Sciences (CA)
- University of Toronto (CA)
- Institute for Work & Health (CA)
- Corresponding author
- Manuel, Douglas G
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2006-03-16
- Volume
- 332
- Issue
- 7542
- Pages
- 659-662
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- PMC
- PMC1403258
- OpenAlex
- W1963936146
- Cited by
- 195
- References
- 27
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 8 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 2 · 2018: 6 · 2017: 8 · 2016: 9 · 2015: 14 · 2014: 7 · 2013: 17 · 2012: 16
- FWCI
- 22.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- BMJ (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Keywords
- coronary artery disease, cardiovascular risk assessment, primary prevention, secondary prevention, risk stratification, prevention
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Coronary Disease, Health Policy, Humans, Hypercholesterolemia, Hypertension, Middle Aged, Risk Factors, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
